+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pregabalin for the treatment of generalized anxiety disorder (GAD) in elderly patients: efficacy as a function of baseline symptom severity



Pregabalin for the treatment of generalized anxiety disorder (GAD) in elderly patients: efficacy as a function of baseline symptom severity



European Psychiatry 22: S336-S337




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 063602075

Download citation: RISBibTeXText

DOI: 10.1016/j.eurpsy.2007.01.1147


Related references

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. International Clinical Psychopharmacology 34(3): 110-118, 2019

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Journal of Clinical Psychiatry 67(5): 771-782, 2006

Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology 25(2): 151-158, 2005

A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 56(9): 558-566, 2011

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 25(2): 151-158, 2005

Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam. Yearbook of Psychiatry and Applied Mental Health 2007: 231-232, 2007

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62(9): 1022-1030, 2005

Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. International Journal of Neuropsychopharmacology 17(5): 685-695, 2014

Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder. Journal of Clinical Psychiatry 65(6): 838-844, 2004

Comorbid generalized anxiety disorder in primary social phobia: Symptom severity, functional impairment, and treatment response. Journal of Anxiety Disorders 14(4): 325-343, July-August, 2000

Long-term efficacy of pregabalin in generalized anxiety disorder. International Clinical Psychopharmacology 23(1): 18-28, 2008

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. International Clinical Psychopharmacology 26(5): 243-251, 2011

Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. International Clinical Psychopharmacology 30(5): 265-271, 2015

Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. International Clinical Psychopharmacology 27(3): 142-150, 2012

Generalized anxiety disorder (GAD): efficacy of standardized Matricaria recutita (German chamomile) extract in the treatment of generalized anxiety disorder. Holistic Nursing Practice 27(6): 366-368, 2014